MED12 and prostate carcinoma: Prior studies have shown that XLID-linked MED12 mutations lead to inactivation of MED12 protein function which subsequently promotes dysregulation of GLI3 signaling [26] Since the mutations found in XLID syndromes closely cluster to the prostate cancer associated MED12 mutations we presume that these mutations similarly lead to inactive MED12 protein function.